Skip to main content

6 Result(s)

within Giovan Giuseppe Di Costanzo Remove this filter

and

  1. Article

    Open Access

    Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenib

    Antiangiogenics are associated with an increased risk of major adverse cardiac and cerebrovascular events (MACE). The identification of at-risk subjects is relevant in the case of hepatocellular carcinoma (HCC...

    Bernardo Stefanini, Francesco Tovoli, Franco Trevisani… in Internal and Emergency Medicine (2024)

    Download PDF (1044 KB) View Article

  2. No Access

    Chapter

    Liver Tumors Laser Ablation

    Laser ablation (LA) is a useful tool to fight liver tumors. This minimally invasive technique is particularly useful in patients affected by hepatocellular carcinoma. In fact, in most of cases these patients a...

    Giovan Giuseppe Di Costanzo, Raffaella Tortora… in Image-guided Laser Ablation (2020)

  3. No Access

    Article

    Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation

    Metronomic capecitabine (MC) is a well-tolerated systemic treatment showing promising results in one retrospective study, as second-line therapy after sorafenib failure, in patients with hepatocellular carcino...

    Franco Trevisani, Giovanni Brandi… in Journal of Cancer Research and Clinical On… (2018)

  4. No Access

    Article

    Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma

    Sorafenib is recommended for the treatment of advanced-stage hepatocellular carcinoma (HCC). Nonetheless, it is expensive, effective in few patients, and may cause significant adverse effects. Therefore, accur...

    Giovan Giuseppe Di Costanzo, Andrea Casadei Gardini, Giorgia Marisi… in Targeted Oncology (2017)

  5. No Access

    Article

    Impact of Diabetes on Outcomes of Sorafenib Therapy for Hepatocellular Carcinoma

    Patients with diabetes are at increased risk of develo** hepatocellular carcinoma (HCC) and have a poorer prognosis as compared to non-diabetics when HCC occurs. Diabetics with non-HCC cancers are at higher ...

    Giovan Giuseppe Di Costanzo, Raffaella Tortora, Filomena Morisco… in Targeted Oncology (2017)

  6. No Access

    Article

    Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma

    The incidence of hepatocellular carcinoma (HCC) is increasing worldwide and the proportion of older patients with HCC is expected to steadily rise in the next years. Sorafenib is the standard of care for patie...

    Giovan Giuseppe Di Costanzo, Raffaella Tortora, Massimo De Luca… in Medical Oncology (2013)